Liver disease and cirrhosis
4 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- HOSPITAL CLINIC DE BARCELONA
Major Barcelona teaching hospital providing clinical expertise, patient cohorts, and trial sites across liver disease, HIV, neuroscience, and chronic care research.
“Core clinical partner in CARBALIVE, LIVERHOPE, and related projects focused on decompensated cirrhosis therapies, nanoporous carbon treatments, and simvastatin/rifaximin strategies.”
PrimaryES64 projects - FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Barcelona hospital research institute specializing in stroke, clinical trial platforms, rare diseases, and translational nanomedicine with direct patient access.
“Participated in CARBALIVE (nanoporous carbon therapy for liver cirrhosis), LIVERHOPE (simvastatin/rifaximin for decompensated cirrhosis), and liver-related arms of EU-PEARL.”
ES46 projects - INNOVATION ACTA SRL
Italian SME providing clinical trial design and regulatory support for advanced therapies, immunomodulation, and multi-center European health studies.
“LIVERHOPE tested simvastatin and rifaximin for decompensated cirrhosis; LiverScreen focused on population-based screening for liver fibrosis across Europe.”
SMEIT9 projects - AZIENDA OSPEDALE UNIVERSITA PADOVA
Italian university hospital specializing in liver disease research, autoimmune disease stratification, and clinical validation within European consortia.
“Four projects (CARBALIVE, LIVERHOPE, ChiLTERN, LiverScreen) span cirrhosis treatment, liver fibrosis screening, pediatric liver tumors, and NAFLD.”
PrimaryIT7 projects